About Volastra Therapeutics
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
|
|
|
11-50 employees
View all Volastra Therapeutics employees
|
|
Biotechnology
|
|
$1M–$10M
|
|
(646) 760-0000
|
|
1361 Amsterdam Ave, 520, New York, New York 10027, US
|
|
2019
|
Volastra Therapeutics Alternatives
Frequently Asked Questions about Volastra Therapeutics
Charles Hugh-jones is the CEO of Volastra Therapeutics. To contact Charles Hugh-jones email at [email protected] or [email protected]. Or you may call +1.9739783462
The decision makers in Volastra Therapeutics are Charles Hugh-jones Frcp, Christina Eng, Derek Cogan, etc. Click to Find Volastra Therapeutics decision makers emails.
Volastra Therapeutics headquarters is located at 1361 Amsterdam Ave, 520, New York, New York 10027, US.
Volastra Therapeutics generates an estimated $1M–$10M annually, based on industry analysis and publicly available market data.
You can contact Volastra Therapeutics by calling (646) 760-0000.
Volastra Therapeutics Staff Directory
Search Volastra Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
